Drug Trial Radar · NCT07826052
Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
494
Planned (sponsor's estimate)
Start
Sep 15, 2026
Primary completion
Sep 30, 2031
Study completion Oct 1, 2035
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, open-label, multicenter, single-arm Phase II clinical trial. Based on the use of CDK4/6 inhibitors in endocrine-sensitive luminal-type (ER+/HER2-) breast cancer, it aims to explore the possibility of chemotherapy exemption in elderly patients (aged \>65 years) with lymph node-positive, HR+/HER2- breast cancer.
Conditions
- Breast Cancer
- Adjuvant Therapy
Interventions
CDK4/6 inhibitorDrug
(abemaciclib/ribociclib/dalpiciclib/palbociclib)
Endocrine Therapy (Optional)Drug
Endocrine therapy (letrozole/anastrozole/exemestane)
Primary outcomes
What the sponsor says the trial is designed to measure.
- 5-years Invasive disease free survivalTime frame: 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.